Exigyn Intelligence

Live benchmarking sourced from SEC EDGAR and ClinicalTrials.gov

Request Access
E
Exigyn Intel
live
Gilead — R&D spend by quarter▍
Sources
SEC EDGAR
ClinicalTrials.gov
Peer set
Answer
$1.43BR&D expense · latest quarter
R&D expense ($B, quarterly)
1.31
1.36
1.40
1.43
Q1Q2Q3Q4
Parsed from 10-Q XBRL · +6% YoY